UVI 3003
CAS: 847239-17-2
Ref. 3D-XIB23917
| 5mg | A consultar | |
| 10mg | A consultar | |
| 25mg | A consultar | |
| 50mg | A consultar | |
| 100mg | A consultar |
Información del producto
- 3-[4-Hydroxy-3-(5,5,8,8-Tetramethyl-3-Pentoxy-6,7-Dihydronaphthalen-2-Yl)Phenyl]Prop-2-Enoic Acid
UVI 3003 is a drug that is being developed for the treatment of cancer. It has been shown to activate the transcription factor, RAR-related orphan receptor alpha (RARα), which regulates the expression of basic proteins, fatty acids, and growth factors. UVI 3003 also activates Toll-like receptors (TLR) and increases the expression of TLR4 and TLR9. These receptors are responsible for initiating an immune response against bacteria in cells. The activation of TLR leads to a downregulation of these receptors, which leads to a reduction in inflammation caused by infection with bacteria. UVI 3003 has been shown to reposition drugs that have already been approved for other indications because it has the ability to inhibit cancer cell proliferation in vitro.
Propiedades químicas
Consulta técnica sobre: 3D-XIB23917 UVI 3003
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
